Biomarker Core

生物标志物核心

• 批准号: 10668261
• 负责人: ADAM M BRICKMAN
• 金额: $ 34.91万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10668261
• 关键词: APLP1 gene; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Apolipoproteins; Biological; Biological Markers; Blood; Cerebrospinal Fluid; Cerebrovascular Disorders; Cholesterol Homeostasis; Classification Scheme; Clinical; Cognitive aging; Collaborations; Communities; Data; Data Sources; Data Store; Databases; Dementia; Detection; Development; Diagnostic; Disease; Endosomes; Etiology; Goals; Hemorrhage; Heterogeneity; Human; Immune response; Immunologic Markers; Infarction; Information Systems; International; Light; Liquid substance; MRI Scans; Magnetic Resonance Imaging; Measurement; Methods; Molecular; Nerve Degeneration; Participant; Pathway interactions; Plasma; Positron-Emission Tomography; Process; Protocols documentation; Radiology Specialty; Research; Research Personnel; Research Proposals; Resources; Scanning; Scientist; Secure; Sensitivity and Specificity; Standardization; Stream; Technology; Thick; Training; Universities; White Matter Hyperintensity; Work; brain magnetic resonance imaging; cerebrovascular; data exchange; exosome; imaging biomarker; improved; in vivo; instrumentation; interest; magnetic resonance imaging biomarker; neurofilament; neuroimaging; neuroimaging marker; next generation; novel; novel marker; participant enrollment; potential biomarker; programs; single molecule; sulfated glycoprotein 2; tau Proteins; trafficking; training opportunity

BIOMARKER CORE PROJECT SUMMARY/ABSTRACT The ability to study Alzheimer’s disease (AD) and related disorders has been revolutionized by the development and application of in vivo biomarkers. Analysis of cerebrospinal fluid (CSF), positron emission tomography (PET), and magnetic resonance imaging (MRI) allow operational measurement of amyloid, tau, and neurodegeneration (A/T/N), the major pathophysiological changes that define AD. Moreover, improved sensitivity and specificity of instrumentation applied to biofluid data, of neuroimaging protocols, and of analytic approaches both enable and necessitate the development, refinement, and discovery of novel biomarkers in any comprehensive AD research program. The Columbia University ADRC Biomarker Core embraces these theme and will derive standard biofluid and MRI biomarkers for all ADRC participants; serve as a central hub for human biofluid, PET, and MRI-based biomarker research conducted within the cognitive aging and dementia community at Columbia University; develop and implement novel biomarkers; and provide training opportunities for investigators interested in incorporating AD-related biomarkers into their research. The Biomarker Core leverages unique data sources, infrastructural, and intellectual strengths already in place and comprises a team of close-collaborating investigators instrumental to the majority of ongoing AD biomarker studies at Columbia University. The Biomarker Core will analyze research grade MRI scans acquired from harmonized clinical scans, from ongoing studies, or de novo for neurodegenerative and cerebrovascular markers. The Core features a newly-acquired single molecule array (Simoa) Benchtop Multiplexed Biomarker Detection Analyzer and Mesoscale Discovery (MSD) platform for analysis of CSF and blood and development of novel biomarkers. These resources will be used to derive existing blood- and CSF-based biomarkers and to develop novel ones. The deep biomarker characterization of all ADRC participants and close interaction with the other Cores will increase understanding of disease etiology and heterogeneity. The Biomarker Core has the following aims: 1) To harmonize, bank, and disseminate fluid and neuroimaging biomarker data derived from participants enrolled by the Clinical Core; 2) To quantitate biofluid biomarkers and MRI markers of neurodegeneration and cerebrovascular disease, according to the A/T/N classification scheme; 3) To develop, optimize, and implement biomarkers of the three thematic biological pathways: immune response, cholesterol metabolism, and endosomal trafficking; 4) To provide intellectual, analytic, and infrastructural support to local investigators interested in incorporating blood-based, CSF, MRI, and PET imaging biomarkers into their Alzheimer’s-related research programs; and 5) To provide training and training opportunities for the next generation of diverse scientists interested in incorporating biomarkers into the study of cognitive aging and dementia.

生物标志物核心项目总结/摘要 研究阿尔茨海默氏病（AD）和相关疾病的能力已经发生了革命性的发展， 以及体内生物标志物的应用。脑脊液（CSF）分析，正电子发射断层扫描 (PET)和磁共振成像（MRI）允许对淀粉样蛋白、tau和 神经变性（A/T/N）是定义AD的主要病理生理学变化。此外，改善 应用于生物流体数据的仪器的灵敏度和特异性、神经成像协议的灵敏度和特异性以及分析的灵敏度和特异性。 这些方法使得在任何疾病中开发、改进和发现新的生物标志物成为可能，也是必要的。 全面的AD研究计划。哥伦比亚大学ADRC生物标志物核心包含这些主题 并将为所有ADRC参与者导出标准生物流体和MRI生物标志物;作为人类 在认知老化和痴呆社区内进行的基于生物流体、PET和MRI的生物标志物研究 在哥伦比亚大学;开发和实施新的生物标志物;并提供培训机会， 有兴趣将AD相关生物标志物纳入其研究的研究人员。 生物标志物核心利用了独特的数据源，基础设施和知识优势已经到位 并由一组密切合作的研究人员组成，这些研究人员对大多数正在进行的AD生物标志物 在哥伦比亚大学学习。生物标志物核心将分析研究级MRI扫描， 协调临床扫描，来自正在进行的研究，或神经退行性疾病和脑血管疾病的新发扫描 标记。The Core采用新收购的单分子阵列（Simoa）台式多重生物标志物 检测分析仪和Mesoscale Discovery（MSD）平台，用于分析CSF和血液以及开发 新的生物标志物。这些资源将用于获得现有的基于血液和CSF的生物标志物， 开发新的。所有ADRC参与者的深层生物标志物表征以及与 其他核心将增加对疾病病因和异质性的理解。生物标志物核心具有 1）协调、储存和传播来自以下的流体和神经成像生物标志物数据： 临床核心招募的参与者; 2）定量生物流体生物标志物和MRI标志物， 根据A/T/N分类方案，神经退行性疾病和脑血管疾病; 3）为了发展， 优化，并实施三个主题生物途径的生物标志物：免疫反应，胆固醇 代谢和内体运输; 4）为当地提供智力，分析和基础设施支持 有兴趣将血液、CSF、MRI和PET成像生物标志物纳入其研究的研究者 老年痴呆症相关的研究计划;和5）为下一个提供培训和培训机会 一代不同的科学家有兴趣将生物标志物纳入认知老化的研究， 痴呆